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Background: Our past researches suggested that L. barbarum exhibits direct neuroprotective and immune
regulatory effects on the central nervous system, which are highly related to the events involved in the spinal cord
injury, but not yet been investigated. Immune responses play an important role in the development of the
pathology after secondary injury, particularly the M1 and M2 types of macrophage, on which special emphasis was
laid in this study.
Methods: In our previous studies L. barbarum was administrated orally from 7 days before the injury to ensure a
stabilized concentration in the blood. For clinical application, L. barbarum can only be administered after the injury.
Therefore, both pre-injury and post-injury administration protocols were compared. In vivo and in vitro studies were
conducted and analyzed immunohistochemically, including Western blotting.
Results: The lesion size in the pre-treated group was much larger than that in the post-treated group. To explain this
difference, we first studied the effect of L. barbarum on astrocytes, which forms the glial scar encircling the lesion.
L. barbarum did not significantly affect the astrocytes. Then we studied the effect of L. barbarum on microglia/
macrophages, particularly the M1 and M2 polarization. After spinal cord injury, the deleterious M1 cells dominant the early
period, whereas the beneficial M2 cells dominate later. We found that in the pre-treated group L. barbarum significantly
enhanced the expression of M1 cells and suppressed that of M2 cells, while in the post-treated group LBP markedly
promoted the activity of M2 cells. This explained the difference between the pre- and post-treated groups.
Conclusions: Lycium barbarum has been wildly accepted to have beneficial effects in various central nervous system
diseases. Our finding of deleterious effect of LBP administered at early period of spinal cord injury, indicates that its
application should be avoided. The substantial beneficial effect of LBP when administered at later stage has an important
impact for clinical application.
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Spinal cord injury (SCI) has long been a focus of research,
from both basic scientific and clinical therapeutic points
of view [1,2]. We have previous studied early neurosurgery
after spinal cord contusion on 30 ASIA-A (complete para-
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reproduction in any medium, provided the ordegree of locomotion, the best results fell in a group of pa-
tients who were operated 4–14 days after SCI, in which
70% could walk with a pair of crutches or without any
support. Immune response is one of the most important
pathological events following SCI. Therefore, to further
improve the clinical result, one of the crucial aspects is to
investigate the changes and mechanism of immune re-
sponses after SCI. In SCI the immune response is a double
edged sword [4-7], particularly the M1 and M2 types of
macrophage [8]. In general, M1 is detrimental, whereas
M2 is protective [5,7,8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Lycium barbarum (also named Fructus Lycii or Wolf-
berry), an upper class Chinese medicine in Chinese
pharmacopoeia, is believed to be beneficial to the eye, kid-
ney and liver and anti-aging. Lycium barbarum polysac-
charide (LBP), the main content of Lycium barbarum,
was found to serve most beneficial functions of wolfberry
[9,10]. Our past researches suggested a direct neuropro-
tective effect on CNS of LBP, in models of Alzheimer's dis-
ease (Amyloid-β toxicity) [9-14], glutamate excitotoxicity
[15], and Ocular hypertension [16-18], by down-regulation
of c-Jun N-terminal signaling, RNA-dependent protein
kinase phosphorylation, caspase-3 and caspase-2 activities,
endoplasmic reticulum stress and up-regulation of Akt
signaling or crystalline [11-13,15,17,18]. In Ocular hyper-
tension model, we found a correlation between microglial
activation and protection of RGC by LBP [16,17]. The im-
mune regulation of LBP is also observed in mice and in
human peripheral blood mononuclear cells [19-21]. It has
been reported that LBP can be anti-oxidative [22-26].
The effects of LBP are highly related to SCI, but have
not yet been studied. Its immune regulation and micro-
glia/macrophage activation are particularly interesting,
because of the importance of immune responses in SCI,
especially the M1 and M2 types of macrophages. The
aim of the present study was to investigate the effects of
LBP in SCI and whether LBP could be a potential thera-
peutic medicine.
Methods
LBP administration
LBP was extracted as reported [16-18]. For animal experi-
ments, the LBP was dissolved in warm double-distilled
water, and fed through a nasogastric tube, 10 mg/kg, 2/day,
throughout the experiment. For cell culture, 100 μg/ml of
LBP was prepared and filtered through a 0.20 μm hole size
microfilter (Dismic-25, Advantec, Stord, Norway).Animal grouping
Sixty male Sprague–Dawley (SD) rats (220 ~ 250 g), pro-
vided by the Animal Center of the Fourth Military Medical
University, were maintained with temperature and light
(12-h light/dark cycle) controlled. Food and water were
provided ad libitum. Two plans of drug administration
were designed. (1) In our previous studies, to ensure that
the concentration of LBP in the blood had been stabilized
at the time the insults happened, LBP was orally adminis-
tered for 7 consecutive days in advance till the animals
were sactificed. This was followed in the present study
(LBP-pre group). (2) From clinical application of view,
LBP can only be given after the injury. The administration
of LBP started on the 7th day until the animals were
sacrificed (LBP-aft group).Animals were randomly divided into 6 groups. 1. LBP-
pre group, 20 LBP treated and 20 vehicle control, with
similar sub-grouping at 7 d and 14 d (n = 10, 6 for immu-
nohistochemistry, 4 for western blotting). 2. LBP-aft group
(14 d), 10 LBP treated and 10 vehicle control. In each of
them, 6 rats for immunohistochemistry and 4 for western
blotting.
The animal experiments were approved by the Animal
Care Committee of the Fourth Military Medical University.
In vitro study
Two types of cells were used: rat brain primary astrocyte
of and murine N9 microglial cell line [27,28].
The primary astrocytes were isolated and purified from
whole brain of newborn SD rat. Briefly, the brain was cut
into small pieces and trypsinized to separate the cells,
which were then cultured in 75 cm2 tissue culture flasks
with DMEM medium containing 10% FBS, 100 μmol/L
non-essential amino acids, 5 μg/ml insulin, 100 U/mL
penicillin and 100 μg/mL streptomycin. When the cul-
tured cells got confluent (7–10 d), the flask was shaken
overnight (200 rpm at 37°C) to detach the microglia and
oligodendrocytes. The remained cells were cultured 3 pas-
sages to purify the astrocytes. The purity of the primary
astrocytes was determined by immunocytochemistry. Over
95% of the cells were GFAP immunoreactive. The primary
astrocytes were seeded in identical density onto 10 mm
circular slides in 24-well plate for immunocytochemistry,
or directly into 6-well plate for western blotting, TNFα
(20 ng/ml, Sigma, St. Louis, MO, USA), IFNγ (20 ng/ml,
Sigma, St. Louis, MO, USA), LPS (200 ng/ml, Sigma, St.
Louis, MO, USA) had been reported to induce astrocyte
activation in vitro [29-32]. After incubating for 2 days with
LBP, TNFα + IFNγ + LPS or TNFα + IFNγ + LPS + LBP,
the level of GFAP expression was assessed. The incubation
medium served as the negative control.
The murine N9 microglial cells, originally developed
by P. Ricciardi-Castagnoli [33] were maintained in
DMEM with 5% FCS. In experiment, cells were seeded
in 6-well plate in an identical density. LPS (200 ng/ml) +
IFNγ (20 ng/ml) and IL-4 (20 ng/ml, Sigma, St. Louis,
MO, USA) were reported to induce M1 and M2
polarization of macrophages, respectively [5-7,34].
Surgery
Tazlaff ’s spinal cord lateral compression model [35] was
followed. Briefly, a thin metal plate was attached onto the
inner side of one blade of the forceps to leave 0.5 mm
between the tips of the forceps when fully closed. The rats
were anesthetized with 1% sodium pentobarbital (50 mg/
kg) i.p. A 3~4 cm dorsal midline incision, centering at T8
vertebral spine, was made, followed by bilateral laminec-
tomy of T8 vertebra to expose the spinal cord. The blades
of the forceps were lowered along the lateral sides of the
Figure 1 Lesion size and immunofluorescence intensity A-F. GFAP immunostaining. G. Lesion size. H. Immunofluorescence intensity. The
lesion area is delineated along the inner boundary of the GFAP immunostained astrocytic scar (dash line). The immunofluorescence was
evaluated in the areas 0.5 mm rostral and caudal to the lesion (solid line). In B the ventral part of the spinal cord was broken. A straight line
between the broken ends was drawn (arrow). Also, at the upper right and left parts (arrow heads) there were two small parts where the solid line
was drawn outside of the section. The areas of these two small parts were measured. They covered less than 1% of the entire interested area,
and were neglected in the evaluation. A-D. LBP-pre group: A, C. 7 d and 14 d vehicles; B, D. 7 d and14 d corresponding LBP treated cases. At
both 7 d and 14 d the lesion sizes were significantly larger than that of the control (G), but there was no significant difference in the
immunofluorescence intensity of GFAP (H). E, F. LBP-aft 14 d group. Unlike the LBP-pre group, the lesion area was smaller in the drug group.
Similar to the LBP-pre group there was no significant difference in the immunofluorescence intensity between the control and LBP treated
groups. *p < 0.05, compared to the corresponding vehicle control. Bar = 1 mm.
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Figure 2 Effect of LBP on GFAP expression in primary astrocyte. Astrocyte stimulated with TNFα + IFNγ + LPS displayed hypertrophic
appearance (C) and higher GFAP expression (E, F), compared to the vehicle group (A). Cells treated with LBP (B) or LBP plus TNFα + IFNγ + LPS
(D) showed no difference in staining intensity (E) and GFAP level (F), versus the corresponding controls, respectively (A, C). Bar = 50 μm.
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cord was compressed in 8–10 seconds and remained
in place for 20 seconds before the blades were let loose in
8–10 seconds and the forceps withdrawn. The skin incision
was then closed. Manual evacuation of urinary bladder was
performed twice daily until normal micturition resumed.Tissue preparation
The rats were sacrificed by an overdose of sodium
pentobarbital (100 mg/kg) and perfused intra-cardially
with 100 ml of warm normal saline followed by 400 ml
4% cold paraformaldehyde in phosphate buffer (pH 7.4).
Following perfusion, a 2 cm spinal cord segment, with
the injured site at the middle, was removed and put into
25% sucrose in phosphate buffer at 4°C until it sank.Serial 14 μm frozen sagittal sections were cut on a cryo-
stat, and mounted on slides in 5 sets.
Immunofluorescence staining
The immunostaining was conducted at room temperature.
The tissue sections or cell culture slides were rinsed with
0.01 M PBS and then blocked with 1% BSA (Sigma) in
PBS containing 0.5% Triton X-100 for 30 min. The
sections were then incubated with primary antibody
over night. After rinsed with PBS, the sections were incu-
bated with the fluorescent second antibody for 2 h. Anti-
bodies against markers of astrocyte (anti-GFAP, rabbit
polyclonal, Dako Cytomaton, Denmark A/S, 1:5000, or),
rat lysosomal membrane marker (anti-ED1, mouse mono-
clonal, Serotec, Raleigh, NC, USA; 1:400), iNOS (rabbit
polyclonal, Cambridge, MA, USA, 1:50) and Arginase1
Figure 3 Effects LBP on ED1 expression ED1 levels were
normalized to the corresponding vehicle controls at the same
time point in the same group. LBP-pre groups exhibited an
increased ED1 expression, relative to the controls at corresponding
time. No measurable difference was found between LBP-aft group
and their control. *p < 0.05, compared to the corresponding
vehicle control.
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California, USA,1:200) were used. The corresponding
fluorescent secondary antibodies were purchased from
Molecular Probes, Oregon, USA. Omission of the primary
antibody served as the negative control. The sections were
observed under Olympus BX-51 microscopy or FV1000
laser scanning confocal microscopy.
Tissue section selection
The most important pathological changes after SCI occur
in the main mass of the gray matter. In the central region
of the spinal cord, there is only a narrow gray commissure,
but there are many branches of blood vessels in the ventral
fissure. The bleeding following crushing can be rather pro-
fuse and the extent of the blood squeezing along the dorsal
funiclus is unpredictable, adding in a factor of individual
variation of the data, thereby interferes the statistic analysis.
In our pilot experiment, we succeeded in solving the prob-
lem by omitting the central sagittal sections and selected
sections 200 to 600 μm from the central canal, where the
main body of the gray matter was located. We followed this
protocol in the present study.
Microphotography for cultured cell
The primary astrocytes were cultured on 10 mm circular
slide slides. By rotating 60°, 6 fields of each slide center-
ing at the point 0.25 cm to the slide edge were micro-
photographed under a 40 × objective.Measurement of lesion area
The lesion areas in the 7 d and 14 d groups were outlined
along the inner edge of the GFAP strongly positive astro-
cytes. The areas were measured in photoshop CS3.
Fluorescence intensity quantification
All the microphotos of an experiment group were taken
with identical setting and the fluorescence intensity was
measured.
For tissue sections, the integrated optical density
(IOD) and area of the chosen region (AREA) were mea-
sured by Image-Pro Plus 6.0 and immunostaining inten-
sity was expressed as IOD/AREA.
For primary astrocyte, the IOD and area of the whole
picture (AREA) were measured, and the immunostaining
intensity was calculated as above.
Cell counting
In sections triple-stained with GFAP, ED1 and iNOS or
Arg1, cell counting was performed in the area within 1 mm
rostral or caudal to the lesion edge. On each side (rostral or
caudal) in each section, ED1+iNOS+ or ED1+iNOS+ cells
were counted in areas of 250 × 250 μm. Due to the irregu-
larity of the distal edge, at least three squares could be
chosen at random. The cell counts were normalized to
mm2 cord section.
Western blotting
For protein samples from the spinal cord, a 0.5 mm seg-
ment of the spinal cord, centering at the injury site, was
dissected out from the sacrificed animal. The cord was
placed in cold lysis buffer and homogenized on ice using a
tissue homogenizer (Tissue Tearor 985370, Biospec Prod-
ucts, Bartlesville OK, USA). The samples were centrifuged
(12000 RMP) 4°C for 5 min. Afterwards, the supernatants
were flashly frozen and stored at −80°C until used.
For cultured microglia or astrocyte, 200 μL cold lysis
buffer was added into the well of 6-well plate for
harvesting. The samples were homogenized with a 200 ml
transferpettor, and then treated as described above.
The samples were boiled for 5 min in strong denatur-
ing conditions, loaded on SDS-polyacrylamide gels, and
transblotted onto polyvinylidene difluoride membranes
(Millipore Corporation, Bedford, MA). The blots
were blocked with 1% defatted milk for 1 h at room
temperature and incubated overnight at 4°C with the fol-
lowing antibodies: anti-GFAP (rabbit polyclonal, Anbo,
San Francisco, C.A., USA, 1:800), anti-ED1 (mouse
monoclonal, Serotec, Raleigh, NC, USA, 1:400), anti-
iNOS (rabbit polyclonal, Cambridge, MA, USA, 1:500),
anti-Arginase1 (goat polyclonal, Santa Cruz Biotechnol-
ogy, Santa Cruz, California, USA,1:1000). After incuba-
tion with an HRP-conjugated secondary antibody, the
samples were subjected to enhanced chemiluminescence
Figure 4 Correlation between change of ED1 expression and lesion area. ED1 fluorescence intensity in area outside lesion and within 1 mm
to the edge (two bands rostral and caudal to lesion, outlined by lines on each section) was measured, with the positive labeling within lesion out
of our calculation. Animals given LBP-pre exhibited increased ED1 immunofluorescence intensity at either 7 d (B) or 14 d (D), compared to their
corresponding vehicle groups, respectively (A, 7 d, C, 14 d). And in these animals, the increased ED1 staining intensity correlated with lesion change
induced by LBP, at either 7 d (H) or 14 d (I). In rats treated with LBP-aft, no significant difference was found between LBP group (F) and control (E), at
14 d after injury. *p < 0.05, compared to the corresponding vehicle control; Bar = 1 mm. (G) ED1 fluorescence intensity of LBP-pre and LBP-aft groups.
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was performed in Image-Pro Plus 6.0.
Data analysis
The mean value of selected sections in each rat or se-
lected images on each slide was calculated for statistic
analysis. Each in vitro experiment was repeated 3 inde-
pendent times at least. For western blotting results,
change of abundancy of protein was calculated by meas-
uring IOD of a protein divided by IOD of the corre-
sponding β-actin. All data was analyzed using SPSS 12.0.
Unpaired student's t-test was used to compare each
treated samples with the corresponding controls, andCorrelation regression for correlation analysis. Statistic
results were shown as mean ± standard error. P values
less than 0.05 (p < 0.05) was taken as significant.
Results
Effect of LBP on lesion area
In the LBP-pre group the lesion size at 7 d and 14 d was
1.30 and 1.17 mm2, respectively. In the vehicle group, they
were 0.97 and 0.75 mm2, respectively. The differences be-
tween LBP and vehicle were statistically significant at 7 d
(p = 0.028) and 14 d (p = 0.014) (Figure 1A-D, G). In the
LBP-aft group the lesion size was 0.56 mm2 at 14 d, and in
the vehicle group 0.80 mm2. The difference was statistically
Figure 5 Effects LBP on microglia/macrophage activation
(polarization) in SCI. Relative numbers of iNOS/Arg1 ratio to the
corresponding vehicle controls at the same time point in the same
group were shown. In rats treated with LBP-pre, iNOS was up-
regulated and Arg1 down-regulated, with consequent higher ratio
of iNOS/Arg1, compared to vehicle groups, at both 7 d and 14 d,
respectively. Whereas, LBP-aft administration induced both increase
in iNOS and Arg1 level, but finally got a reduced iNOS/Arg1 ratio,
versus its vehicle control at 14 d. *p < 0.05, compared to the
corresponding vehicle control.
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strated that the lesion sizes in the LBP-pre group were lar-
ger than that of the LBP-aft group (p = 0.0026). In short,
LBP could reduce the size of the lesion site; administer of
LBP before the spinal cord injury markedly increased the
lesion. It occurred to us that the difference between the le-
sion sizes of LBP-pre and LBP-aft could be due to the effect
of LBP on astrocytes. Astrocytes form the major part of the
glial scar, which, as a protective measure, limits the lesion
site from expansion. If LBP could inhibit the astrocytes, the
glial scar would be weakened.Effect of LBP on astrocyte
In vivo study
At 7 d and 14 d after SCI, the GFAP immunofluorescence
intensity of the astrocytes in the area 0.5 mm rostral and
caudal to the lesion edge, where most of the reactive astro-
cytes in the gray matter were located, was evaluated. There
was no significant difference between the LBP-pre, LBP-
aft groups, and their respective vehicles, indicating that
LBP does not have influence on astrocytes in SCI
(Figure 1A-F and, H).In vitro study
Given the complexity of in vivo environment that may
counteract the deleterious effect on astrocytes, e.g. M2
macrophage, we conducted in vitro study to verify it.
The TNFα + IFNγ + LPS induced strong GFAP immu-
noreactivity in the cultured primary astrocytes, whereas
the vehicle treated astrocytes showed much weaker im-
munoreactivity. The LBP plus TNFα + IFNγ + LPS and
LBP induced no significant difference in GFAP level,
compared to TNFα + IFNγ + LPS and vehicle group, re-
spectively (Figure 2). The in vitro study lent support to
the in vivo study.
Both the in vivo and in vitro studies demonstrated that
LBP has no effect on astrocytes. We then thought, if the
difference could be due to their effect on microglia/
macrophage.
Effect of LBP on microglia/macrophage
Changes of ED1
Western blotting In the LBP-pre 7 d and 14 d groups
the expressions of ED1 were higher than their respective
controls (p = 0.013 at 7 d, 0.017 at 14 d). In the LBP-aft
group there was no difference in the expressions of ED1
between the drug and control (p = 0.71) (Figure 3).
Immunohistochemistry The microglia and macrophages
were labeled with antibody against ED1. The ED1 positive
cells were predominantly distributed around the injury site.
Their immunoreactivity declined farther away from the le-
sion (Figure 4A-F), in the area 1 mm rostral and caudal to
the lesion edge, the ED1 fluorescence intensity in the LBP-
pre group was increased by 34% at 7 d (Figure 4A, B) and
51% 14 d (Figure 4C, D) compared to their respective ve-
hicle group (p = 0.0037 at 7 d, 0.01 at 14 d) (Figure 4G).
The correlation coefficients between the fluorescence
intensity and the lesion size were 0.74 at 7 d (p = 0.004)
(Figure 4H) and 0.68 at 14 d (p = 0.014) (Figure 4I). There
was no significant change in ED1 immunostaining intensity
between the LBP-aft group and the vehicle (p = 0.35)
(Figure 4E, F, G).
Thus, both the Western blotting and immunohistochem-
ical studies suggested that even the lesion size was highly
correlated with the increase in ED1 immunoreacivity, it
was not the result of LBP administration. We then turn to
investigate whether it was their effect on M1 and M2 cells
that makes the difference.
Effect of LBP on M1 and M2
In vivo study
Western blotting The effect of LBP on M1 and M2 was
evaluated by the changes of iNOS and Arginase1 (Arg1)
expressions. The expressions of iNOS in the LBP-pre 7 d
Figure 6 Quantitative evaluation of the M1 and M2 macrophage/microglia. By immunofluorescence staining, most iNOS or Arg1 were
expressed in ED1 positive cells. In LBP-pre groups at 7 d and 14 d, there were elevated ED1 expression, increased ED1+iNOS+ cells and reduced
ED1+Arg1+ (M2) cell, in comparison to the controls. LBP-pre treated animals showed an increased number of M2 cells. Bar = 20 μm.
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trols. The Arginase1 levels in the corresponding groups
were all decreased. The ratio between the iNOS and Arg1
rose by 1.35 fold at 7 d and 36% at 14 d. In the LBP-aft
group at 14 d, both the iNOS and Arg1expressions were
up-regulated, however, the increment of Arg1 was greaterthan that of iNOS, leading to a reduction of their ratio by
32% (Figure 5).
Immunohistochemistry Since it has been reported that
iNOS can be expressed in neurons and neutrophils, im-
munohistochemistry was used to confirm if the iNOS/
Figure 7 Statistic result of the number of M1 and M2
macrophage/microglia and M1/M2 ratio. LBP-pre groups showed
increased M1 (A), reduced M2 cells (B) and a remarkable higher M1/
M2 ratio (C), relative to their corresponding controls. LBP-aft animals
exhibited no difference in M1 number (A) however increased M2
cells (B), resulting a significantly lower M1/M2 ratio (C), versus the
controls. *p < 0.05, compared to the corresponding vehicle controls. Figure 8 Effects of LBP on murine N9 microglial cell N9 cells
were treated with different medicines. The iNOS level was shown
as relative number to that of the vehicle group, and the Arg1 level and
iNOS/Arg1 ratio were normalized to that of IL-4 group. Vehicle treated
N9 cells displayed mild iNOS and little Arg1. LPS + IFNγ and IL-4 induced
markedly enhanced M1 and obvious M2, respectively. LBP alone and
allied with IL-4 led to increased iNOS and suppressed Arg1 expression,
compared to vehicle and IL-4, respectively. *p < 0.05, **p < 0.01,
compared to the corresponding controls treated with same medicine
short of LBP.
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pressing iNOS or Arg1 in the area 1 mm rostral and caudal
to the lesion edge were counted. The LBP-pre animals at
7 d and 14 d showed increased ED1+iNOS+ (M1) and re-
duced ED1+Arg1+ (M2) cells, exhibiting significantly higher
M1/M2 ratio, relative to the corresponding controls. In
Figure 9 The in vivo LBP-pre and LBP-aft study was mimicked
in N9 cells. N9 cells were treated with different medicines for
2 days. Relative numbers to the first group were shown. N9 cells
were incubated with LBP for first one day and LBP plus LPS + IFNγ +
IL-4 for next day, and presented a higher M1 and suppressed M2
polarization compared to its LBP-free control. If the cells were
treated with LPS + IFNγ + IL-4 for first day, and the LBP plus LPS +
IFNγ + IL-4 for the second, LBP group displayed reduction in iNOS
and elevation in Arg1 expression in comparison to its control that
stimulated with LPS + IFNγ + IL-4 for corresponding 2 days. *p < 0.05,
**p < 0.01, compared to the corresponding controls treated with
same medicine but lack of LBP. L,Iγ,IL4, abbreviation
for LPS + IFNγ + IL-4.
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number between the two groups, however, treated animals
displayed an increased number of M2 cells, with a resultant
lower M1/M2 ratio (Figures 6, 7).
In vitro study The N9 microglial cell line was used. Vari-
ous M1 activators, LPS + IFNγ, and M2 activator, IL-4,
were applied. iNOS and Arg1 were used as M1 and M2
markers, respectively, the results were evaluated with
Western blotting.
The first part of the experiment was to study the effect
of LBP, including LBP and the vehicle, LBP plus LPS +
IFNγ and LPS + IFNγ, LBP plus IL-4 and IL-4, six groups.
It had been demonstrated that LBP up-regulated iNOS,
but no Arg1expression could be detected. The vehicle
showed only mild level of iNOS. The LBP plus LPS + IFNγ
and LPS + IFNγ groups displayed similar results as the
LBP group. IL-4 caused decrease in iNOS and increase in
Arg1 and LBP plus IL-4 induced a reversal of IL-4 effects
(Figure 8).
To investigate the difference between the LBP-pre and
LBP-aft groups, two experiments were designed. For LBP-
pre, the N9 cells were incubated with LBP on the first one
day and LBP plus LPS + IFNγ + IL-4 on the next day.
Omission of LBP served as the control. For LBP-aft, the
N9 cells were treated with LPS + IFNγ + IL-4 on the first
day and on the next day the cells were treated with LBP
plus LPS + IFNγ + IL-4 or the control LPS + IFNγ + IL-4.
In the LBP-pre study, the iNOS expression was elevated
and Arg1 reduced. The M1/M2 ratio was higher than its
LBP free control. In LBP-aft, the iNOS expression was re-
duced and Arg1 elevated. The M1/M2 ratio was lower
than the LBP free control (Figure 9).
Discussion
The lesion size in the LBP-pre group was larger than that
in the LBP-aft group came as a surprise to us and we had
to face the challenge of finding out the explanation.
Since the astrocytic scar is important in limiting the le-
sion size [36-38], we first examined the effect of LBP on as-
trocytes. The result of our in vitro study demonstrated that
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effects of the LBP-pre and LBP-aft groups on microglia/
macrophage. Our ED1 immunohistochemical study showed
that, though the immunointensity was highly correlated
with the lesion size, the enhanced immunointensity was
not the result of LBP administration. There are reports
demonstrating that after SCI the macrophages response
actively and play an important role in the development of
secondary injury [5-7]. Furthermore, M1 produces high
level of oxidized metabolic substances, such as NO, super-
oxides, pro-inflammatory factors, IL-12, IL-1β, IL-15, IL-18,
TNF-α, CCL15, and CCL20. Furthermore, its expression
of chondroitin sulphate proteoglycan is 17 times higher
than that on M2 cells. On the contrary, M2 secretes anti-
inflammatory factor IL-10 and TGF-β. In addition, they can
secrete various neurotrophines, like NGF, BDNF, NT-3 and
neurotrophic factors, including CNTF, IGF, EGF, PDGF,
GDNF [39,40]. M1 can inhibit neurite outgrowth of dorsal
root ganglion, while M2 has the opposite effects. In vitro
evidence shows that M1 macrophage can directly induce
neuronal death [41-43]. We then, therefore, focused on the
changes in M1 and M2 macrophages. Our data showed
that M1 dominated right after the insult and gradually
sifted to M2 dominance. LBP treatment before the injury
enhances M1 and suppresses M2, whereas LBP adminis-
tered 7 days after the injury increased the number of
M2 cells.
Lycium barbarum has been wildly accepted to have
beneficial effects in various central nervous system ill-
ness. Our finding of deleterious effect of LBP adminis-
tered at early period of spinal cord injury, so that its
application should be avoided, and the substantial bene-
ficial effect of LBP when administered at later stage has
an important impact for clinical application.Conclusions
Our previous studies have demonstrated that LBP has
many beneficial effects in the central nervous system, in-
cluding retina. But its effect had never been studied in
spinal cord injury. The present study found that major ef-
fect of LBP in spinal cord injury is via its action on M1
and M2 types of macrophages. It is well known that M1
macrophages is deleterious, which dominate the first
period of spinal cord injury and gradually shift to M2
dominance, which is benificial. Administration of LBP at
the beginning of the injury enhances M1 and suppresses
M2, whereas administration of LBP from 7th day on after
injury has significant beneficial effect in reducing the sec-
ondary injury. This finding is an important issue that is
valuable for its translation to clinical application.Competing interests
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